Press Release
<p>WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD</p>
<p><strong>CONTACT:</strong> Christine Stroup <strong>FOR IMMEDIATE RELEASE</strong><br/>
Kovak-Likly Communications<br/>
(203) 762-8833 or CStroup@KLCpr.com </p>
<p><strong>WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD</strong><br/>
<strong>Ferring Pharmaceuticals Announces 2006 My Little Miracle Essay Contest</strong> </p>
<p>If you are a mom who has successfully given birth using Ferring Pharmaceuticals’
infertility products, you can win a $10,000 education fund or one of 11 other
prizes to support your child’s future. To be eligible, all you need to do is
write a brief essay on your journey to achieve parenthood and its impact on
your life. </p>
<p>Ferring’s My Little Miracle Essay Contest is open to women who have been
successfully treated with BRAVELLE<sup>®</sup> (urofollitropin for injection, purified),
MENOPUR <sup>®</sup> (menotropins for injection, USP), REPRONEX<sup>®</sup> (menotropins for injection,
USP), or a combination of these medications. The contest celebrates the miracle
of birth for these mothers who have faced infertility and continues Ferring’s
tradition of providing value to their patients by offering education funds for
the winners’ children. </p>
<p>Ferring is also awarding a $2,500 education fund to the runner up and 10
honorable mention winners will each receive $500. Since announcing the
first contest in 2004, Ferring has awarded $50,000 in education funds to
its winners. </p>
<p>Essays should not exceed 800 words, must be written in English, include the
entrant’s name, address, phone number and age, as well as the child(ren)’s
name and age(s) and be submitted with a contest application and labeled
photo. Entries must be postmarked by June 30, 2006. Winners will be
announced at the 62nd Annual Meeting of the American Society for
Reproductive Medicine (ASRM), October 21-25, 2006. </p>
<p>For more details and a contest application visit www.ferringfertility.com
or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative. </p>
<p>BRAVELLE<sup>®</sup> (urofollitropin for injection, purified), MENOPUR <sup>®</sup> (menotropins
for injection, USP) and REPRONEX<sup>®</sup> (menotropins for injection, USP), like all gonadotropins,
are potent substances capable of causing mild to severe adverse reactions, including
OHSS (incidence of 6.0%, 3.8% and 3.5%, respectively), with or without pulmonary or
vascular complications, in women undergoing therapy for infertility. </p>
<p>The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader
in naturally occurring protein hormones. Only physicians thoroughly familiar
with infertility treatment, including the risk of multiple births and adverse
reactions, should prescribe these medications. Like other products for ovarian
stimulation, treatment with BRAVELLE<sup>®</sup>, MENOPUR <sup>®</sup> and/or REPRONEX<sup>®</sup> may result
in multiple gestations. </p>
<p># # # </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
